Cargando…

Recurrent cardiovascular events in patients with type 2 diabetes and haemodialysis: analysis from the 4D Study

BACKGROUND: In the ‘Die Deutsche Diabetes Dialyse Studie’ (4D Study), treatment of patients with type 2 diabetes mellitus (T2DM) on haemodialysis (HD) with atorvastatin compared with placebo had no significant effect on the first composite primary major adverse cardiovascular event (MACE) endpoint o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Marx, Nikolaus, Wanner, Christoph, Jankowski, Joachim, März, Winfried, Krane, Vera, Genser, Bernd
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10539202/ https://www.ncbi.nlm.nih.gov/pubmed/37779851 http://dx.doi.org/10.1093/ckj/sfad029

Ejemplares similares

Soluble suppression of tumorigenesis-2 is a strong predictor of all-cause, cardiovascular and infection-related mortality risk in haemodialysis patients with diabetes mellitus
por: Hammer, Fabian, et al.
Publicado: (2022)

Vitamin D deficiency is associated with sudden cardiac death, combined cardiovascular events, and mortality in haemodialysis patients
por: Drechsler, Christiane, et al.
Publicado: (2010)

Risk factors for retinopathy in hemodialysis patients with type 2 diabetes mellitus
por: Müller, Michael, et al.
Publicado: (2020)

Homoarginine, heart failure, and sudden cardiac death in haemodialysis patients
por: Drechsler, Christiane, et al.
Publicado: (2011)

Aldosterone and cortisol affect the risk of sudden cardiac death in haemodialysis patients
por: Drechsler, Christiane, et al.
Publicado: (2013)

Change in N-terminal-pro-B-type-natriuretic-peptide and the risk of sudden death, stroke, myocardial infarction, and all-cause mortality in diabetic dialysis patients
por: Winkler, Karl, et al.
Publicado: (2008)

The association between parathyroid hormone and mortality in dialysis patients is modified by wasting
por: Drechsler, Christiane, et al.
Publicado: (2009)

Transthyretin Predicts Cardiovascular Outcome in Hemodialysis Patients With Type 2 Diabetes
por: Henze, Andrea, et al.
Publicado: (2012)

The effect of spironolactone on diastolic function in haemodialysis patients
por: Hauser, T., et al.
Publicado: (2021)

Platelet Reactivity and Cardiovascular Mortality Risk in the LURIC Study
por: Berger, Martin, et al.
Publicado: (2023)

Effect of amlodipine on cardiovascular events in hypertensive haemodialysis patients
por: Tepel, Martin, et al.
Publicado: (2008)

Cardiovascular Disease in Chronic Kidney Disease: Pathophysiological Insights and Therapeutic Options
por: Jankowski, Joachim, et al.
Publicado: (2021)

Intronic Variants in OCT1 are Associated with All-Cause and Cardiovascular Mortality in Metformin Users with Type 2 Diabetes
por: Schweighofer, Natascha, et al.
Publicado: (2020)

Baseline Cardiovascular Risk Factor Control in Patients With Type 2 Diabetes and Coronary Disease Versus Stroke: Secondary Analysis of Cardiovascular Outcome Trials
por: Balasubramanian, Priyadarshini, et al.
Publicado: (2023)

Plant sterols and cardiovascular disease: a systematic review and meta-analysis(†)
por: Genser, Bernd, et al.
Publicado: (2012)

Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient-level pooled analysis of prospectively adjudicated cardiovascular events
por: Rosenstock, Julio, et al.
Publicado: (2015)

Static intra-access pressure ratio and cardiovascular events in patients undergoing haemodialysis
por: Jeon, Hee Jung, et al.
Publicado: (2020)

Study design of DIACORE (DIAbetes COhoRtE) – a cohort study of patients with diabetes mellitus type 2
por: Dörhöfer, Lena, et al.
Publicado: (2013)

Association of myeloperoxidase with total and cardiovascular mortality in individuals undergoing coronary angiography—The LURIC study
por: Scharnagl, Hubert, et al.
Publicado: (2014)

C-Peptide Levels Are Associated With Mortality and Cardiovascular Mortality in Patients Undergoing Angiography: The LURIC study
por: Marx, Nikolaus, et al.
Publicado: (2013)

Epicardial adipose tissue thickness is not associated with adverse cardiovascular events in patients undergoing haemodialysis
por: Chen, Ying-Chih, et al.
Publicado: (2020)

Vitamin D and Cardiovascular Disease: An Updated Narrative Review
por: Zittermann, Armin, et al.
Publicado: (2021)

Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk
por: Zinman, Bernard, et al.
Publicado: (2017)

Apolipoprotein CIII predicts cardiovascular events in patients with coronary artery disease: a prospective observational study
por: Katzmann, Julius L., et al.
Publicado: (2020)

The effect of empagliflozin on the total burden of cardiovascular and hospitalization events in the Asian and non‐Asian populations of the EMPA‐REG OUTCOME trial of patients with type 2 diabetes and cardiovascular disease
por: Kaku, Kohei, et al.
Publicado: (2022)

Measuring intradialyser transmembrane and hydrostatic pressures: pitfalls and relevance in haemodialysis and haemodiafiltration
por: Ficheux, Alain, et al.
Publicado: (2019)

Design and rationale of a randomised controlled trial comparing apixaban to phenprocoumon in patients with atrial fibrillation on chronic haemodialysis: the AXADIA-AFNET 8 study
por: Reinecke, Holger, et al.
Publicado: (2018)

Recurrence of Cardiovascular Events in Patients With Type 2 Diabetes : Epidemiology and risk factors
por: Giorda, Carlo B., et al.
Publicado: (2008)

Erratum to: Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic-range proteinuria and type 2 diabetes (t2d): the carmelina randomised controlled trial
por: Wanner, Christoph, et al.
Publicado: (2021)

Association of gait speed and grip strength with risk of cardiovascular events in patients on haemodialysis: a prospective study
por: Kuki, Atsumi, et al.
Publicado: (2019)

The Effect of Polyphenol-Rich Interventions on Cardiovascular Risk Factors in Haemodialysis: A Systematic Review and Meta-Analysis
por: Marx, Wolfgang, et al.
Publicado: (2017)

Neopterin is associated with cardiovascular events and all-cause mortality in renal transplant patients
por: Pihlstrøm, Hege, et al.
Publicado: (2014)

Response to Comment on: Wehr et al. Low Free Testosterone Levels Are Associated With All-Cause and Cardiovascular Mortality in Postmenopausal Diabetic Women. Diabetes Care 2011;34:1771–1777
por: Lerchbaum, Elisabeth, et al.
Publicado: (2012)

Risk for recurrent cardiovascular disease events among patients with diabetes and chronic kidney disease
por: Hubbard, Demetria, et al.
Publicado: (2021)

Risk of recurrent cardiovascular events in coronary artery disease patients with Type D personality
por: Torgersen, Kristin Stensland, et al.
Publicado: (2023)

Advances in the management of cardiovascular risk for patients with type 2 diabetes: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes
por: Schernthaner, Guntram, et al.
Publicado: (2017)

The new marker YKL-40, a molecule related to inflammation, is associated with cardiovascular events in stable haemodialysis patients
por: Vega, Almudena, et al.
Publicado: (2019)

Blood Pressure and Mortality in the 4D Study
por: Yazdani, Babak, et al.
Publicado: (2023)

Hypercholesterolemia Diagnosis, Treatment Patterns, and 12-Month Target Achievement in Clinical Practice in Germany in Patients with Familial Hypercholesterolemia
por: Gitt, Anselm K., et al.
Publicado: (2022)

Vitamin D Levels Predict All-Cause and Cardiovascular Disease Mortality in Subjects With the Metabolic Syndrome: The Ludwigshafen Risk and Cardiovascular Health (LURIC) study
por: Thomas, G. Neil, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_c8inqaq3m7u3pqngb46fvr6mcn